Germline Fumarate Hydratase Mutations in Families with Multiple Cutaneous and Uterine Leiomyomata by Martínez Mir, Amalia et al.
Germline Fumarate Hydratase Mutations in Families with Multiple Cutaneous 
and Uterine Leiomyomata 
Amalia Martinez-Mir*, Benjamin Glaser†, Gary S. Chuang*, Liran Horev‡, Arie Waldman§, Danielle 
E Engler*, Derek Gordon§§, Lynda J Spelman¶, Ioannis Hatzibougias#, Jack Green**, Angela 
M Christiano*,†† and Abraham Zlotogorski‡ 
*Department of Dermatology, Columbia University, USA 
††Department of Genetics & Development, Columbia University, USA 
§§Laboratory of Statistical Genetics, Rockefeller University, New York, New York, USA 
†Endocrine & Metabolism Service, Hebrew University-Hadassah Medical Center, Jerusalem, Israel 
‡Department of Dermatology, Hebrew University-Hadassah Medical Center, Jerusalem, Israel 
§Department of Dermatology, Haemek Medical Center, Afula, Israel 
#Institute of Pathology, Thessaloniki, Greece 
¶Southeast Dermatology, Brisbane, Queensland, Australia 
**Department of Dermatology, St. Vincent's Hospital, Melbourne, Australia 
Correspondence: Abraham Zlotogorski MD, Department of Dermatology, Hadassah Medical Center, PO 
Box 12000, Jerusalem, Israel, 91120. Email: zloto@cc.huji.ac.il 
Abstract 
Germline mutations in the fumarate hydratase gene (FH) predispose to multiple cutaneous and 
uterine leiomyoma syndrome (MCL) and MCL associated with renal cell cancer. MCL is inherited 
in an autosomal dominant pattern, manifesting as skin leiomyoma and uterine fibroids in affected 
individuals. Fumarate hydratase, a component of the tricarboxylic acid cycle, acts as a tumor 
suppressor gene in the development of cutaneous and uterine leiomyoma and renal cell cancer in 
this syndrome. Here we report the clinical and mutational analysis of five families with MCL, with 
the identification of five new mutations affecting highly conserved residues of the FH protein. 
These results provide further evidence for the role of the FH gene in the pathogenesis of MCL. 
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Cutaneous leiomyomas are rare, benign tumors arising from the arrector pili muscle of hair follicles. 
Multiple cutaneous and uterine leiomyoma syndrome (MCL; MIM #150800), in which affected 
individuals develop associated skin and uterine leiomyomas, is a disorder inherited in an autosomal 
dominant pattern. The skin lesions usually appear between the early teens and the fourth decade of 
life. For the majority of affected women, uterine fibroids of early onset usually require 
hysterectomy or myomectomy (Stewart, 2001). In some families with MCL, the disease is 
associated with an additional predisposition to type II papillary renal cell carcinoma (Launonen et 
al, 2001). 
The genetic locus for MCL was recently mapped to chromosome 1q42.3-43 (Alamet al, 2001; 
 Kiuru et al, 2001; Martinez-Mir et al, 2002) and subsequently, mutations in the fumarate hydratase 
gene (FH) were identified (Tomlinson et al, 2002). The gene product for FH is fumarate hydratase, 
part of the tricarboxylic acid cycle involved in energy production for the cell. Dominant mutations 
in FH cause MCL in approximately 59.5% of affected individuals (Tomlinson et al, 2002). Based 
on its role in MCL, FH has been hypothesized to act as a tumor suppressor gene in sporadic tumors 
as well. However, two recent reports show a very low frequency of FHmutations in different types 
of tumors, including uterine and cutaneous leiomyomas, leiomyosarcoma, and renal cell carcinoma 
(Barker et al, 2002; Kiuru et al, 2002). Whether FH plays a role in sporadic tumorigenesis remains 
to be determined. Mutations in three different subunits of succinate dehydrogenase, another enzyme 
of the tricarboxylic acid cycle, also correlate with a high incidence of tumors, in particular, 
hereditary paragangliomas (Baysal et al, 2001). Interestingly, autosomal recessive mutations in 
the FH gene have been implicated in fumarate hydratase deficiency, which presents with 
progressive encephalopathy and developmental delay (MIM #606812). Accordingly,Tomlinson et 
al (2002) reported a patient with fumarase deficiency whose mother, a carrier for an FH mutation, 
developed skin leiomyoma. How these two phenotypically distinct disorders are linked to different 
types and combinations of mutations in FH calls for further investigation. 
In this study, we report the clinical and mutational analysis of five families with MCL. We have 
identified five new mutations in the FH gene, further supporting the role of FH in MCL. 
Materials and methods 
Human subjects 
We have identified five families with dominantly inherited MCL, comprising 16 affected 
individuals available for this study. Blood samples were collected according to the local 
Institutional Review Board. Clinical features and pedigrees of four families were previously 
published in case reports (MCL-1, MCL-2, MCL-3, and MCL-5) (Lun and Spelman, 2000; 
Tsoitis et al, 2001; Alam et al, 2002; Martinez-Mir et al, 2002). 
Mutation analysis 
Genomic DNA was isolated from peripheral blood collected in EDTA-containing tubes using the 
PureGene DNA isolation kit (Gentra Systems, Minneapolis, MN). To screen for mutations in the 
human FH gene, all exons and splice junctions were PCR-amplified from genomic DNA. PCR 
primers are shown in Table I. PCR products were sequenced in an ABI Prism 310 automated 
sequencer, using the ABI Prism BigDye terminator cycle sequencing ready reaction kit (PE Applied 
Biosystems, Foster City, CA), following purification in Centriflex gel filtration cartridges (Edge 
Biosystems, Gaitherburg, MD). Mutations were identified by visual inspection and comparison with 
control sequences generated from unrelated unaffected individuals. 
To confirm the mutations identified, direct and mismatched PCR were used. The nonsense mutation 
Q142X and the missense H275Y and V351L were confirmed by digestion of the corresponding 
PCR products with BstNI, BspHI, and MaeIII, respectively. In the case of S115I, a reverse 
mismatched primer (5'-CCT AAC ATT TCA ATT GCT CTA TAG-3') was used to introduce an 
Alu  I restriction site. Finally, the PCR product corresponding to frameshift mutation 1081del4 was 
run on a polyacrylamide gel and visualized by ethidium bromide staining. 
All five DNA variants were tested in a mixed control population of 46–49 individuals. The 
missense  variants S115I, H275Y, and V351L were tested in an additional sample of 32–43 control 
individuals. 
Results 
Clinical findings 
The patients in the five families with MCL (Figure 1) originated in five different countries, namely, 
two Jewish families from Tunisia (MCL-1) and Ethiopia (MCL-4), Greece (MCL-2), Australia 
(MCL-3), and Puerto Rico (MCL-5). They comprised a total of 11 and 5 affected women and men, 
respectively. Skin leiomyomas were found in 14 individuals, 9 women and 5 men, ranging in age 
from 14 to 55 y. The affected patients reported sensitivity of the lesions to cold temperature and 
touch. Two of the female patients exhibited skin leiomyomas alone, without any uterine 
abnormality. The typical skin lesions are firm, skin colored to red, ranging from a few in number to 
approximately 100 in older individuals (Figure 2). The lesions range between 0.2 and 1.0 cm in 
diameter and cluster with time. 
Of the 9 women with uterine leiomyoma, 7 had coexisting skin leiomyoma and 2 had uterine 
leiomyoma alone. Six of these patients with affected uteri eventually underwent hysterectomy or 
myomectomy. 
Mutation analysis in the FH gene 
We have analyzed five families with dominantly inherited MCL for FH mutations. All were found 
to carry heterozygous mutations in the FH gene (Table II). None of these mutations have been 
previously reported in patients with MCL or fumarate hydratase deficiency, and each of them was 
unique to a single family. The fact that they have not been detected in the control population 
excludes them as common polymorphisms. 
A C>T transition at nucleotide position 553, which results in the nonsense mutation Q142X (amino 
acid residue 185 in the mitochondrial isoform), was identified in family MCL-2, and a deletion of 
four nucleotides in exon 7 was found in family MCL-5. This frameshift mutant allele is the result of 
a 4-bp deletion starting at any position between nucleotides 1081–1083, creating a premature 
termination codon 12 amino acids downstream of the deletion site. Three missense mutations were 
also identified: a G>T transversion at nucleotide position 473 in exon 4, leading to the missense 
mutation S115I (mitochondrial amino acid residue 158; family MCL-4), a C>T transition at 
position 952 in exon 7 resulting in the missense mutation H275Y (mitochondrial amino acid residue 
318; family MCL-1), and a G>C transversion at position 1180 in exon 8, creating the missense 
mutation V351L (mitochondrial amino acid residue 394; family MCL-3). Exon number and 
nucleotide positions are derived from the FH sequence (Accession No. 18549070). The amino acid 
position for the cytosolic isoform is given, for comparison with the previously reported mutations 
(Tomlinson et al, 2002; Table II). 
Discussion 
In this study, we have identified five new FH"mutations" in MCL families, further supporting the 
role of this housekeeping gene in tumorigenesis. The nature of these mutations, including non-
sense, frameshift, and missense mutations, clearly supports the role of the FH gene in MCL. 
Nonetheless, the involvement of a housekeeping gene such as FH in tumorigenesis unveils new 
questions about the etiologic mechanism underlying MCL. 
Our study has identified a heterozygous nonsense (Q142X) and a frameshift mutation (1081del4) in 
two of the families. The most likely fate of the mRNA of these mutant alleles would be nonsense-
mediated mRNA decay, where the nonsense-bearing mRNA is recognized and degraded soon after 
transcription (Frischmeyer and Dietz, 1999). Unfortunately, mRNA samples from these families 
were not available for further testing and therefore other possible mechanisms such as translation 
into a truncated protein or exon skipping cannot be ruled out. 
Regarding the three missense changes identified in our study, S115I (MCL-4), H275Y (MCL-1), 
and V351L (MCL-3), the possibility of these being rare polymorphisms cannot be completely 
excluded, because a mixed control population was used owing to unavailability of a sufficient 
number of ethnically matched controls. This is especially true for V531L, where both amino acids 
consist of hydrophobic side chains with only one carbon difference. It is noteworthy, however, that 
7 of the 17 mutations reported by Tomlinson et al (2002) were also missense mutations. The 
affected amino acid residues S115, H275, and V351 are conserved among human, pig, rat, and 
mouse FH. 
Cosegregation between the mutations and the MCL phenotype was confirmed for families MCL-1 
(H275Y) and MCL-3 (V351L), for which blood samples from several affected family members 
were available. These two missense variants show reduced penetrance for the skin and uterine 
lesions. H275Y was identified in family MCL-1 (Figure 1), in which we had previously performed 
linkage studies (Martinez-Mir et al, 2002). Restriction analysis in all family members showed that 
12 individuals, 7 women and 5 men, were heterozygous for the mutation. Of the 7 carrier women, 4 
presented with both skin and diagnosed or suspected uterine lesions (hysterectomy in III-17 and III-
19, diagnosed myoma in IV-12, and menorrhagia in V-12), 2 presented with skin lesions alone (III-
21 and IV-2), and 1 was an asymptomatic female (V-2). With the exception of V-17, all carrier men 
suffered from skin leiomyomata. Thus, only two young asymptomatic carriers were identified, V-2 
(age 19) and V-17 (age 18). V-17 was reported to carry the disease-associated haplotype during our 
studies to refine the MCUL1 locus (Martinez-Mir et al, 2002). V-2, on the other hand, showed a key 
recombination event within the disease-associated haplotype (Martinez-Mir et al, 2002). Owing to 
the fact that V-2 was an unaffected individual and that the location and identity of the causative 
gene was still unknown at the time these studies were performed, her carrier status as an 
asymptomatic carrier or unaffected could not be established. With the identification of the FH gene 
by Tomlinson et al (2002), we confirmed that V-2 did indeed carry the disease-associated haplotype 
and, as shown here, an FH mutation. 
In family MCL-3 (Figure 1), on the other hand, the V351L missense substitution was present in 
three women, one of them with both uterine and skin involvement and the remaining two with only 
uterine myoma. The grandmother in this family, reported to have uterine polyps on a biopsy report, 
did not carry the mutation. For family MCL-2 (Q142X; Figure 1) the mutation was only present in 
the affected individual and his mother and absent in the unaffected father and sibling. Since no 
family history of MCL was reported for the affected member of this family, the carrier mother will 
be reexamined for skin and uterine lesions. The missense variant S115I in family MCL-4 was 
present in the affected family member only and absent in the remaining three unaffected siblings 
(Figure 1). The parents of these individuals were not available for the study. Finally, only one 
individual from family MCL-5 (Figure 1, Figure 2), an affected woman, was available for 
examination and was heterozygous for the frameshift mutation. None of the families studied here 
suffered from any other type of tumor, including papillary renal cell cancer. 
In summary, of 11 female patients, 7 exhibited concurrent skin and uterine leiomyoma involvement. 
Of the remaining 4 affected female patients, 2 had skin lesions only and 2 had uterine leiomyoma 
alone. Patients from the same family may display different phenotypic expression of the disease. 
For example, in family MCL-3, a mother with uterine leiomyoma and no skin lesions had two 
daughters, one with both skin and uterine lesions and the other with uterine involvement only. 
Seventeen of 42 families reported by Tomlinson et al (2002) did not display mutations in the FH 
 gene. The rate of mutation detection in our study, on the other hand, reached 100%.Tomlinson et 
al (2002) performed single-strand conformation polymorphism and conformation-specific gel 
electrophoresis as mutation detection methods in some of their families versus direct sequencing in 
our study. This could account for the lower mutation rate in the original report. Overall, it still 
remains possible that the predisposition to MCL is genetically heterogeneous. 
One of the implications of gene identification for inherited susceptibility to tumorigenesis is the 
possible role they may play in the more common sporadic presentation of the same type of tumors. 
Families with MCL present with benign skin and uterine leiomyomas, the latter being a major 
public health issue. In addition, the aggressive papillary renal cell carcinoma can also be associated 
with MCL, as well as leiomyosarcoma (Launonen et al, 2001). Based on this hypothesis, two 
groups have recently searched for mutations in the  FH gene in different types of tumors. Kiuru et 
al (2002)  have analyzed a total of 200 sporadic tumors, including uterine and cutaneous 
leiomyomas, leiomyosarcomas, and papillary renal cell carcinomas. However, only five  FH  
mutations were identified. Barker et al (2002), on the other hand, studied 26 leiomyosarcomas and 
129 uterine leiomyomas. In this case, no FH mutations were identified, although LOH for 1q and 
1q42-43 was detected in 50 and 5% of leiomyosarcomas and leiomyomas, respectively. 
Collectively, these data suggests either that  FH  does not play a major role in the development of 
sporadic tumors or that the pathologic mechanism of FH in MCL involves events different from 
somatic mutations. 
The identification of the particular FH mutation in each MCL family will allow for close follow-up 
of those individuals at risk for the development of the aggressive papillary renal cell cancer 
(Kiuru et al,  2001;  Launonen et al, 2001). Establishing the etiologic mechanisms of MCL may 
facilitate development of new therapeutic options for affected patients. 
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Figures 
Figure I 
 Pedigrees with MCL. Black, gray, and empty symbols, affected, unknown, and unaffected family 
members, respectively. Asterisks, individuals whose blood samples were available, except in MCL-
1 where blood samples for most family members were available. 
Figure II 
 
Clinical picture of cutaneous leiomyoma. Clustering of skin leiomyoma lesions can be observed 
on upper back (A) and arm (B). 
Tables 
Table I. PCR primers for amplification of the FH gene 
Exon Forward primer Reverse primer Size (bp) 
1 CCCAGAAATTCTACCCAAGC AGGGCTGAAGGTCACTGC 214 
2 TGATCCTGGGTTTCTTTTCAAC ATGAATACAGCCTACTTCATCC 240 
3 CCAAAATAATAAACTTCCATGC ATGGGTCTGAGGTTATTAAG 221 
4 CTGTATTCAAACTCTGTGGC TTATAACCAAAAAACAGCAAAGC 288 
5 GTTTTTGTTGCCTCTGATTTAAC TGGCCATTTGTACCAAGCTC 290 
6 GAGTAACTTGTAAGCTATTAGG AATGTACAGACCACGTA 285 
7 TAACTTGTTCACCCATCTAGG CTAGTCAAGTTTTAGCTCCAAC 287 
8 TTAGTCTTTACTCTGTCATTGG TAATAAGCCTTTGGTCAAAAAAC 212 
9 ATTGTATATTTACTGTCAACCAG AAACACTGATCCACTTGTCTCT 356 
10 CTGCTAACCCATATGTCGTC CGTTTTTAAGAAATGGGAGTCTG 252 
 
Table II. Germline FH mutations in MCL families 
Family Wild-type sequence Mutant sequence Amino-acid changea Exon 
MCL-4 AGC ATC S115I 4 
MCL-2 CAG TAG Q142X 4 
MCL-1 CAT TAT H275Y 7 
MCL-5 GAAAATG-AACCA GAAAACCA 4-bp del between amino acids 318 and 319 7 
MCL-3 GTC CTC V351L 8 
 
a Amino-acid positions are derived from the cytosolic enzyme sequence (468 amino acids). The 
exon number corresponds to the entire gene; exon 1 encodes the 43 amino acids that form the 
mitochondrial signal peptide and the first amino acid of the cytosolic protein. 
